

해외 바이오의약품 임상 현황 ('23년 11월 4주)

한국바이오의약품협회, 2023.11.28.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.

URL을 클릭하시면 세부 정보 페이지로 연결됩니다.

- 출처: ClinicalTrials.gov

- 모니터링 기간: 2023.11.20.~2023.11.26.

- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 10건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06096779	A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis	Drug: Atezolizumab Drug: Bevacizumab	Genentech, Inc.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06096779
NCT06068868	Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)	Drug: ABBV-787	AbbVie	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06068868
NCT06027229	Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations	Biological: NVX-CoV2372	University of Wisconsin, Madison Novavax	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06027229
NCT06016179	Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer	Drug: Tocilizumab	Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06016179
NCT06116786	A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer	Drug: JNJ-86974680 Drug: Cetrelimab Radiation: Radiation Therapy	Johnson & Johnson Enterprise Innovation Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06116786
NCT06077760	A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)	Biological: V940 Biological: Pembrolizumab Other: Placebo	Merck Sharp & Dohme LLC ModernaTX, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06077760
NCT06091865	A Study to Compare How Well Odronektamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma	Drug: Odronektamab Drug: Rituximab Drug: Cyclophosphamide Drug: Doxorubicin Drug: Vincristine Drug: Prednisone/Prednisolone	Regeneron Pharmaceuticals	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06091865
NCT06063967	A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.	Drug: Risankizumab SC Drug: Placebo for risankizumab	AbbVie	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06063967
NCT06090539	A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas	Drug: BMS-986458 Drug: Rituximab	Bristol-Myers Squibb	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06090539
NCT06129864	A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy	Drug: volrustomig	AstraZeneca	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06129864

해외 바이오의약품 임상 현황 ('23년 11월 4주)

한국바이오의약품협회, 2023.11.28.

○ 영국 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06129864	A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy	Drug: volrustomig	AstraZeneca	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06129864

○ 프랑스 2건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06090539	A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas	Drug: BMS-986458 Drug: Rituximab	Bristol-Myers Squibb	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06090539
NCT06129864	A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy	Drug: volrustomig	AstraZeneca	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06129864

○ 중국 8건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06135155	A Clinical Trial to Compare Pharmacokinetics of Two Different PEG-rhGH Preparations	Drug: PEG-rhGH with new preparation Drug: PEG-rhGH with present preparation	Changchun GeneScience Pharmaceutical Co., Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06135155
NCT06127303	Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC	Drug: Toripalimab Other: Cryoablation	Shanghai Chest Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06127303
NCT06125405	Study of the Telitacept in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic Syndrome	Drug: Telitacept	The Children's Hospital of Zhejiang University School of Medicine	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06125405
NCT06100653	BCG for Therapeutic Use Phase I Clinical Trial	Drug: BCG for therapeutic use	Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06100653
NCT05981235	Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors	Biological: AZD6422 CLDN18.2 CAR-T product	Peking University AstraZeneca	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05981235
NCT05975307	Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation	Drug: Toripalimab Drug: Gemcitabine Drug: Cisplatin Drug: Carboplatin Radiation: Intensity-modulated radiation therapy	Sun Yat-sen University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05975307
NCT05798793	Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma	Drug: Camrelizumab plus TP Drug: TP	Hospital of Stomatology, Wuhan University Jiangsu HengRui Medicine Co., Ltd.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05798793
NCT06136507	Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A	Drug: FRSW107	Jiangsu Gensciences Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06136507

해외 바이오의약품 임상 현황 ('23년 11월 4주)

한국바이오의약품협회, 2023.11.28.

○ 일본 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06129864	A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy	Drug: volrustomig	AstraZeneca	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06129864